Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration
Age-related macular degeneration is a progressive disease resulting in death of the retinal pigment epithelium (RPE) causing distortion to central vision and eventually to legal blindness. Incidence - 1:1359 in the US. Approach is replacement therapy with viable RPE cells delivered on a synthetic membrane mimicking native state with RPE cells on Bruch's membrane.
Open label, single arm study.
Safety. Efficacy - slow disease progression, maintain and restore visual acuity